JPH0227970B2 - - Google Patents

Info

Publication number
JPH0227970B2
JPH0227970B2 JP57046380A JP4638082A JPH0227970B2 JP H0227970 B2 JPH0227970 B2 JP H0227970B2 JP 57046380 A JP57046380 A JP 57046380A JP 4638082 A JP4638082 A JP 4638082A JP H0227970 B2 JPH0227970 B2 JP H0227970B2
Authority
JP
Japan
Prior art keywords
therapeutic agent
active ingredient
pentanol
methyl ester
liver diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP57046380A
Other languages
English (en)
Japanese (ja)
Other versions
JPS58164512A (ja
Inventor
Yoshinori Sakai
Katsuhiro Imaki
Takashi Muryorin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Priority to JP57046380A priority Critical patent/JPS58164512A/ja
Priority to DE3310556A priority patent/DE3310556A1/de
Priority to US06/478,031 priority patent/US4464388A/en
Priority to BE0/210404A priority patent/BE896274A/fr
Publication of JPS58164512A publication Critical patent/JPS58164512A/ja
Publication of JPH0227970B2 publication Critical patent/JPH0227970B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP57046380A 1982-03-25 1982-03-25 プロスタグランジン類似化合物を有効成分として含有する肝臓疾患治療剤 Granted JPS58164512A (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP57046380A JPS58164512A (ja) 1982-03-25 1982-03-25 プロスタグランジン類似化合物を有効成分として含有する肝臓疾患治療剤
DE3310556A DE3310556A1 (de) 1982-03-25 1983-03-23 Verwendung von prostaglandinanalogen
US06/478,031 US4464388A (en) 1982-03-25 1983-03-23 Use of prostaglandin analogues to treat cytodamage
BE0/210404A BE896274A (fr) 1982-03-25 1983-03-25 Nouvelle utilisation d'analogues de prostaglandines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57046380A JPS58164512A (ja) 1982-03-25 1982-03-25 プロスタグランジン類似化合物を有効成分として含有する肝臓疾患治療剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP29170289A Division JPH02160721A (ja) 1989-11-09 1989-11-09 プロスタグランジン類似化合物を有効成分として含有する膵炎治療剤

Publications (2)

Publication Number Publication Date
JPS58164512A JPS58164512A (ja) 1983-09-29
JPH0227970B2 true JPH0227970B2 (en, 2012) 1990-06-20

Family

ID=12745531

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57046380A Granted JPS58164512A (ja) 1982-03-25 1982-03-25 プロスタグランジン類似化合物を有効成分として含有する肝臓疾患治療剤

Country Status (4)

Country Link
US (1) US4464388A (en, 2012)
JP (1) JPS58164512A (en, 2012)
BE (1) BE896274A (en, 2012)
DE (1) DE3310556A1 (en, 2012)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59163365A (ja) * 1983-03-08 1984-09-14 Ono Pharmaceut Co Ltd プロスタグランジン類似化合物
JPS6130554A (ja) * 1984-07-23 1986-02-12 Ono Pharmaceut Co Ltd プロスタグランジン類似化合物のある特定の立体配置を有する異性体及びそれらを有効成分として含有する治療剤
DE3448257C2 (en) * 1984-07-25 1988-08-18 Schering Ag, 1000 Berlin Und 4709 Bergkamen, De Cytoprotective action of prostacyclin derivatives on the kidney
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
US5256696A (en) * 1989-11-22 1993-10-26 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of cardiac dysfunction with 15-ketoprostaglandin compounds
US5254588A (en) * 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
CA2030344C (en) 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
US5380667A (en) * 1992-10-30 1995-01-10 The United States Of America As Represented By The Secretary Of The Air Force Serum bilirubin and liver function tests as risk predictors for coronary artery disease
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
WO1998040073A1 (fr) * 1997-03-13 1998-09-17 Toray Industries, Inc. Medicament pour traiter les lesions vasculaires diabetiques
US6340693B1 (en) 1997-03-14 2002-01-22 Toray Industries, Inc. Protective agent for nervous system structural cells
ATE306256T1 (de) 1999-08-05 2005-10-15 Teijin Ltd Mittel zur besserung der neuropathie, die als wirkstoff stickstoffhaltige verbindungen enthalten
DE10160935A1 (de) * 2001-12-12 2003-07-17 Daimler Chrysler Ag Kraftfahrzeugkühlvorrichtung für elektronische Geräte
BR112013007849A2 (pt) * 2010-10-01 2016-06-07 Rigshospitalet compostos capazes de modular/preservar a integridade endotelial para uso na prevenção ou tratamento de coagulopatia traumática aguda e parada cardíaca com ressuscitação

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4081553A (en) * 1976-02-17 1978-03-28 The Upjohn Company Cytoprotective prostaglandins for use in human intestinal diseases
US4083998A (en) * 1976-02-17 1978-04-11 The Upjohn Company Treatment of inflammatory diseases of the mammalian large intestine with cytoprotective prostaglandins
JPS5395958A (en) * 1977-01-31 1978-08-22 Ono Pharmaceut Co Ltd Prostaglandin analogues and process for their preparation
US4178367A (en) * 1977-02-21 1979-12-11 Ono Pharmaceutical Co. Ltd. Prostaglandin I2 analogues
US4097603A (en) * 1977-09-06 1978-06-27 The Upjohn Company Gastric cytoprotection with non-antisecretory doses of prostaglandins
JPS6022710B2 (ja) * 1977-09-16 1985-06-03 小野薬品工業株式会社 プロスタグランジン類似化合物
JPS5452069A (en) * 1977-09-29 1979-04-24 Ono Pharmaceut Co Ltd Prostaglandin i2 analog compound and its preparation
JPS54125653A (en) * 1978-03-18 1979-09-29 Ono Pharmaceut Co Ltd Prostaglandin i2 analog, its preparation, and drug composition comprising it as active constituent
DE2947526A1 (de) * 1978-11-29 1980-06-12 Ono Pharmaceutical Co Prostacyclin-analoge

Also Published As

Publication number Publication date
DE3310556A1 (de) 1983-11-24
JPS58164512A (ja) 1983-09-29
BE896274A (fr) 1983-09-26
DE3310556C2 (en, 2012) 1991-07-11
US4464388A (en) 1984-08-07

Similar Documents

Publication Publication Date Title
DE3850676T2 (de) Hypotensive okulare Mittel.
JPH0227970B2 (en, 2012)
DD258942A5 (de) Cyclodextrinclathrate von carbacyclinderivaten und ihre verwendung als arzneimittel
EP0310305B1 (en) Cathartics
US5317032A (en) Prostaglandin cathartic
EP0366279A2 (en) Ocular hypotensive agents
US5001154A (en) Fervescence composition
US6956056B2 (en) Method for providing a cathartic effect
US4503068A (en) Use of prostaglandin analogues to treat cytodamage
JP2002534389A (ja) 女性性機能障害の治療のための方法および組成物
AT396687B (de) Cyclodextrinclathrate von 5-cyanoprostacyclinderivaten und ihre verwendung als arzneimittel
EP0069692A1 (de) Neue Carbacycline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE3322893A1 (de) Neue prostacyclinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPS6144819A (ja) プロスタグランジンｉ２類縁化合物を含有する循環改善作用を有する薬剤
JPS5819675B2 (ja) １９ ２０− ビス−ノル−プロスタンサンノ セイホウ
DE68927885T2 (de) Verwendung von isokarbacyclinen zur vorbeugung oder behandlung von organkrankheiten
JPH0480006B2 (en, 2012)
US4443478A (en) Prostaglandin analogues
HU187376B (en) Process for preparing new prostaglandins
JPS5833841B2 (ja) 動脈硬化症用および血糖降下用医薬組成物
JPH05331062A (ja) 抗潰瘍剤
DE2607021A1 (de) Neue blutdrucksenker
EP0410652A2 (en) Use of 15-keto-prostanoic acid derivatives in the manufacture of a medicament for improvement of excretion of potassium ion
JPH0564932B2 (en, 2012)
EP0163672A1 (de) 20-alkyl-7-oxoprostacyclinderivate und verfahren zu ihrer herstellung.